TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis

Cancer Immunology, Immunotherapy

Volumn 58, Issue 3, 2009, Pages 361-371

  Djafarzadeh, Roghieh ^a   Milani, Valeria ^a   Rieth, Nicole ^a   Von Luettichau, Irene ^a,b   Skrablin, Petra S ^b   Hofstetter, Monika ^a   Noessner, Elfriede ^b   Nelson, Peter J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Apoptosis; Hyperthermic therapy; Melanoma; TIMP 1 GPI

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; FAS ANTIBODY; FAS ANTIGEN; GELATINASE A; GELATINASE B; GLYPICAN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CLONOGENIC ASSAY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; IN VITRO STUDY; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING; ZYMOGRAPHY;

ANTIGENS, CD95; APOPTOSIS; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; FLOW CYTOMETRY; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; HYPERTHERMIA, INDUCED; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA; SKIN NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME;

EID: 58149312784     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0559-5     Document Type: Article

References (55)

1. M Egeblad Z Werb 2002 New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2 3 161 174
2. Y Itoh H Nagase 2002 Matrix metalloproteinases in cancer Essays Biochem 38 21 36
3. W Bode K Maskos 2003 Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases Biol Chem 384 6 863 872
4. H Nagase JF Woessner Jr 1999 Matrix metalloproteinases J Biol Chem 274 31 21491 21494
5. K Brew D Dinakarpandian H Nagase 2000 Tissue inhibitors of metalloproteinases: evolution, structure and function Biochim Biophys Acta 1477 1-2 267 283
6. CM Klier EL Nelson CD Cohen R Horuk D Schlondorff PJ Nelson 2001 Chemokine-induced secretion of gelatinase B in primary human monocytes Biol Chem 382 9 1405 1410
7. NM Sorensen P Bystrom IJ Christensen A Berglund HJ Nielsen N Brunner B Glimelius 2007 TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid Clin Cancer Res 13 14 4117 4122
8. K Brand 2002 Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs) Curr Gene Ther 2 2 255 271
9. R Chirco XW Liu KK Jung HR Kim 2006 Novel functions of TIMPs in cell signaling Cancer Metastasis Rev 25 1 99 113
10. ME Medof S Nagarajan ML Tykocinski 1996 Cell-surface engineering with GPI-anchored proteins FASEB J 10 5 574 586
11. R Djafarzadeh A Mojaat AB Vicente I von Luttichau PJ Nelson 2004 Exogenously added GPI-anchored tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) displays enhanced and novel biological activities Biol Chem 385 7 655 663
12. R Djafarzadeh E Noessner H Engelmann DJ Schendel M Notohamiprodjo I von Luettichau PJ Nelson 2006 GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing Oncogene 25 10 1496 1508
13. O Brown RL Cowen CM Preston MG Castro PR Lowenstein 2000 Subcellular post-transcriptional targeting: delivery of an intracellular protein to the extracellular leaflet of the plasma membrane using a glycosyl- phosphatidylinositol (GPI) membrane anchor in neurons and polarised epithelial cells Gene Ther 7 22 1947 1953
14. C Garbe TK Eigentler 2007 Diagnosis, treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 17 2 117 127
15. CA La Porta 2007 Drug resistance in melanoma: new perspectives Curr Med Chem 14 4 387 391
16. F Facchetti S Previdi M Ballarini S Minucci P Perego CA La Porta 2004 Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors Apoptosis 9 5 573 582
17. MS Soengas SW Lowe 2003 Apoptosis and melanoma chemoresistance Oncogene 22 20 3138 3151
18. J Overgaard D Gonzalez Gonzalez MC Hulshof G Arcangeli O Dahl O Mella SM Bentzen 1995 Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology Lancet 345 8949 540 543
19. J van der Zee D Gonzalez Gonzalez GC van Rhoon JD van Dijk WL van Putten AA Hart 2000 Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group Lancet 355 9210 1119 1125
20. EL Jones JR Oleson LR Prosnitz TV Samulski Z Vujaskovic D Yu LL Sanders MW Dewhirst 2005 Randomized trial of hyperthermia and radiation for superficial tumors J Clin Oncol 23 13 3079 3085
21. DL Fraker 2004 Management of in-transit melanoma of the extremity with isolated limb perfusion Curr Treat Options Oncol 5 3 173 184
22. A Sanki PC Kam JF Thompson 2007 Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology Ann Surg 245 4 591 596
23. HH Kampinga 2006 Cell biological effects of hyperthermia alone or combined with radiation or drugs: a short introduction to newcomers in the field Int J Hyperthermia 22 3 191 196
24. V Milani B Frankenberger O Heinz A Brandl S Ruhland RD Issels E Noessner 2005 Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response Int Immunol 17 3 257 268
25. L Rivoltini KC Barracchini V Viggiano Y Kawakami A Smith A Mixon NP Restifo SL Topalian TB Simonis SA Rosenberg 1995 Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes Cancer Res 55 14 3149 3157
26. AC Kirby V Hill I Olsen SR Porter 1995 LFA-3 delta D2: a novel in vivo isoform of lymphocyte function-associated antigen 3 Biochem Biophys Res Commun 214 1 200 205
27. M Mack G Riethmuller P Kufer 1995 A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity Proc Natl Acad Sci USA 92 15 7021 7025
28. J Overgaard HD Suit 1979 Time-temperature relationship the hyperthermic treatment of malignant and normal tissue in vivo Cancer Res 39 8 3248 3253
29. RD Issels A Nagele 1990 Influence of thiols on thermosensitivity of mammalian cells in vitro Methods Enzymol 186 696 708
30. RF Schwabe S Hess JP Johnson H Engelmann 1997 Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies Hybridoma 16 3 217 226
31. E Noessner R Gastpar V Milani A Brandl PJ Hutzler MC Kuppner M Roos E Kremmer A Asea SK Calderwood RD Issels 2002 Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells J Immunol 169 10 5424 5432
32. MW Dewhirst BL Viglianti M Lora-Michiels M Hanson PJ Hoopes 2003 Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia Int J Hyperthermia 19 3 267 294
33. HM Ko JH Kang B Jung HA Kim SJ Park KJ Kim YR Kang HK Lee SY Im 2007 Critical role for matrix metalloproteinase-9 in platelet-activating factor-induced experimental tumor metastasis Int J Cancer 120 6 1277 1283
34. XJ Qu YX Yuan ZG Tian WF Xu MH Chen SX Cui Q Guo R Gai M Makuuchi M Nakata W Tang 2006 Using caffeoyl pyrrolidine derivative LY52, a potential inhibitor of matrix metalloproteinase-2, to suppress tumor invasion and metastasis Int J Mol Med 18 4 609 614
35. FH Igney PH Krammer 2002 Death and anti-death: tumour resistance to apoptosis Nat Rev Cancer 2 4 277 288
36. Q Bao Y Shi 2007 Apoptosome: a platform for the activation of initiator caspases Cell Death Differ 14 1 56 65
37. T Rothhammer I Poser F Soncin F Bataille M Moser AK Bosserhoff 2005 Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration Cancer Res 65 2 448 456
38. MA Karsdal L Larsen MT Engsig H Lou M Ferreras A Lochter JM Delaisse NT Foged 2002 Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis J Biol Chem 277 46 44061 44067
39. SA Illman K Lehti J Keski-Oja J Lohi 2006 Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells J Cell Sci 119 Pt 18 3856 3865
40. ME Polak NJ Borthwick FG Gabriel P Johnson B Higgins J Hurren D McCormick MJ Jager IA Cree 2007 Mechanisms of local immunosuppression in cutaneous melanoma Br J Cancer 96 12 1879 1887
41. BC Barnhart JC Lee EC Alappat ME Peter 2003 The death effector domain protein family Oncogene 22 53 8634 8644
42. M Jaattela 2004 Multiple cell death pathways as regulators of tumour initiation and progression Oncogene 23 16 2746 2756
43. Y Shi 2006 Mechanical aspects of apoptosome assembly Curr Opin Cell Biol 18 6 677 684
44. L Gorelik RA Flavell 2002 Transforming growth factor-beta in T-cell biology Nat Rev Immunol 2 1 46 53
45. LI Gold 1999 The role for transforming growth factor-beta (TGF-beta) in human cancer Crit Rev Oncog 10 4 303 360
46. Peng Y, Gorelik L, Laouar Y, Li MO, Flavell RA (2006) TGFbeta-mediated immunoregulation. Ernst Schering Res Found Workshop, (56):155-60
47. P Conti D Kempuraj K Kandere M Di Gioacchino RC Barbacane ML Castellani M Felaco W Boucher R Letourneau TC Theoharides 2003 IL-10, an inflammatory/inhibitory cytokine, but not always Immunol Lett 86 2 123 129
48. FN Lauw D Pajkrt CE Hack M Kurimoto SJ van Deventer T van der Poll 2000 Proinflammatory effects of IL-10 during human endotoxemia J Immunol 165 5 2783 2789
49. AD Santin PL Hermonat A Ravaggi S Bellone S Pecorelli JJ Roman GP Parham MJ Cannon 2000 Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes J Virol 74 10 4729 4737
50. D Sharma TP Chelvi J Kaur R Ralhan 1998 Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma Melanoma Res 8 3 240 244
51. HD Han MS Choi T Hwang CK Song H Seong TW Kim HS Choi BC Shin 2006 Hyperthermia-induced antitumor activity of thermosensitive polymer modified temperature-sensitive liposomes J Pharm Sci 95 9 1909 1917
52. T Minko RI Pakunlu Y Wang JJ Khandare M Saad 2006 New generation of liposomal drugs for cancer Anticancer Agents Med Chem 6 6 537 552
53. EM Noorda BC Vrouenraets OE Nieweg JM Klaase J van der Zee BB Kroon 2003 Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb Melanoma Res 13 4 395 399
54. HI Robins F D'Oleire E Grosen D Spriggs 1997 Rationale and clinical status of 41.8 degrees C systemic hyperthermia tumor necrosis factor, and melphalan for neoplastic disease Anticancer Res 17 4B 2891 2894
55. E Pagani S Falcinelli R Pepponi M Turriziani P Caporaso S Caporali E Bonmassar S D'Atri 2007 Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity Int J Oncol 30 2 443 451